Bob Duggan, Summit CEO (via Summit Investments)
December 21, 2021 11:25 AM ESTUpdated 12:16 PM
R&D

Bil­lion­aire Bob Dug­gan's new an­tibi­ot­ic play fails a Phase III tri­al, and in­vestors aren't hap­py

Nicole DeFeudis

Editor

Bob Dug­gan — the bil­lion­aire in­vestor fa­mous for turn­ing Phar­ma­cyclics from a pen­ny stock to a $20 bil­lion com­pa­ny — placed a hand­some bet on the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times